Evidence map›Paper›PMID 40243672›Full record

ArticleInternational journal of molecular sciences2025

Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian Cancer Cell Lines.

Mahfuza Marzan, Nuzhat Nowshin Oishee, Abigail Oluwafisayo Olatunji, Abiral Hasib Shourav, Radwan Ebna Noor, Aaron Joshua Astalos, James W Leahy, Mildred Acevedo-Duncan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. PKC-International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mahfuza MarzanDepartment of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA.
Nuzhat Nowshin OisheeDepartment of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA.
Abigail Oluwafisayo OlatunjiDepartment of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA.ORCID 0000-0002-8793-8178
Abiral Hasib ShouravDepartment of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA.ORCID 0000-0001-8579-7909
Radwan Ebna NoorDepartment of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA.
Aaron Joshua AstalosDepartment of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA.ORCID 0009-0000-7081-7508
James W LeahyDepartment of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA.ORCID 0000-0003-3647-4489
Mildred Acevedo-DuncanDepartment of Chemistry, University of South Florida, 4202 E Fowler Ave, CHE 205, Tampa, FL 33620, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is the most lethal gynecological cancer, with a 5-year survival rate of approximately 50%. Mutation in the p53 gene and overexpression of the atypical protein kinase C iota (PKC-ι) are two phenomena widely manifested in ovarian cancer. This study investigated the role of PKC-ι-specific inhibitor ICA-1S and proteasome inhibitor MG-132 in ovarian cancer cell lines. To discern the result, cell proliferation assays, cytotoxicity assays, Western blotting, immunofluorescence, flow cytometry, small interfering RNA, and co-immunoprecipitation techniques were applied. ICA-1S and MG-132 were found to inhibit the proliferation of ovarian cancer cell lines significantly. ICA-1S reduced the level of oncogenic PKC-ι as expected. In addition, ICA-1S and MG-132 both were able to decrease the level of mutated p53 in the ES-2 cell line through separate pathways. On the contrary, MG-132 increased the level of wild-type p53 in the HEY-T30 cell line by inhibiting proteasomal degradation. MG-132 also induced apoptosis and autophagy in the ovarian cancer cell lines. We concluded that ICA-1S alone or in combination with MG-132 could be a potential treatment for mutated p53-containing and PKC-ι-overexpressing ovarian cancers.

Indexed as

ApoptosisLeupeptinsOvarian NeoplasmsProteasome InhibitorsProtein Kinase CTumor Suppressor Protein p53AutophagyCell Line, TumorCell ProliferationFemaleHumansIsoenzymesMutationProtein Kinase C-lambdaProteolysisbenzyloxycarbonylleucyl-leucyl-leucine aldehydeIsoenzymesLeupeptinsProteasome InhibitorsProtein Kinase CProtein Kinase C-lambdaTP53 protein, humanTumor Suppressor Protein p53ovarian cancerp53PKC-ιproteasome inhibitor MG-132

Identifiers

PMID40243672
PMCPMC11988680

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.